This summer has been unusually busy for drug reviewers at the China State Drug Administration (CSDA), which has granted green lights to seven new drugs in the past few weeks.
Among these are two immuno-oncology agents, the PD-1 checkpoint inhibitors Bristol-Myers Squibb Co.’s Opdivo (nivolumab) and Merck &...